News

• EI-001, Elixiron's drug candidate for treating vitiligo, has received approval for a clinical trial in China from the National Medical Products Administration
• September 10, 2023
• Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein
• August 25, 2023
• A new mechanism of IFN-γ in the pathogenesis of vitiligo reveald by a discovery from the collaborative research of Chang-Gung University and Elixiron
• April 25, 2023
• Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI 001 for the Treatment of Hemophagocytic Lymphohistiocytosis
• September 6, 2022
• Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
• August 2, 2022
• Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response
• July 20, 2022
• Elixiron Immunotherapeutics Receives Grant from the Alzheimer’s Association to Trial Microglia-Targeting Immunotherapy
• July 12, 2022
• Elixiron dives into IFNγ and CSF-1R with pathway-centric approach
• June 9, 2022
• A bifunctional anti-PD-L1 antibody/IL-10 fusion protein targeting exhausted T cells for cancer immunotherapy
• October 11, 2021
• Elixiron Immunotherapeutics Closes $27 Million Series A-1 Financing Round to Progress Alzheimer’s Disease and Vitiligo Clinical-Stage Assets
• August 23, 2021
• Elixiron Immunotherapeutics Awarded Alzheimer’s Association Grant to Target Microglia in Alzheimer’s Disease
• August 26, 2020
• Taiwan Biotech and Elixiron Immunotherapeutics: Pharma Boardroom Interview
• June 26, 2019
• A potent and selective cFMS inhibitor EI-1071 inhibits CSF1R signaling and regulates tumor associated macrophages
• September 14, 2018
• Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization
• September 1, 2018

Contact